BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24124391)

  • 1. The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival.
    Tantraworasin A; Saeteng S; Lertprasertsuke N; Arayawudhikul N; Kasemsarn C; Patumanond J
    Cancer Manag Res; 2013; 5():327-36. PubMed ID: 24124391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
    Huang ZL; Cao X; Luo RZ; Chen YF; Zhu LC; Wen Z
    Oncol Lett; 2016 Jan; 11(1):299-305. PubMed ID: 26870207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
    Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
    Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zhao H; Zhang H; Du Y; Gu X
    Tumour Biol; 2014 Dec; 35(12):12679-88. PubMed ID: 25227663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
    Lafuente-Sanchis A; Zúñiga Á; Galbis JM; Cremades A; Estors M; Martínez-Hernández NJ; Carretero J
    Clin Transl Oncol; 2016 Aug; 18(8):798-804. PubMed ID: 26542178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
    Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of the mRNA expression of
    Sun S; Shi W; Wu Z; Zhang G; Yang BO; Jiao S
    Exp Ther Med; 2015 Sep; 10(3):937-941. PubMed ID: 26622418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic Analysis of ERCC1, RRM1 and p53 Expressions in Postoperative Stage I-II Lung Cancer.].
    Wang H; Feng J; Zhang X; Yang X; He W; Sha H; Han B
    Zhongguo Fei Ai Za Zhi; 2009 May; 12(5):387-95. PubMed ID: 20719132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
    Leng XF; Chen MW; Xian L; Dai L; Ma GY; Li MH
    J Exp Clin Cancer Res; 2012 Mar; 31(1):25. PubMed ID: 22439756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.
    Wang X; Zhao J; Yang L; Mao L; An T; Bai H; Wang S; Liu X; Feng G; Wang J
    Med Oncol; 2010 Jun; 27(2):484-90. PubMed ID: 19488864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
    Su C; Zhou S; Zhang L; Ren S; Xu J; Zhang J; Lv M; Zhang J; Zhou C
    Med Oncol; 2011 Dec; 28(4):1411-7. PubMed ID: 20467918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
    Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
    Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer.
    Tantraworasin A; Saeteng S; Lertprasertsuke N; Arreyakajohn N; Kasemsarn C; Patumanond J
    Cancer Manag Res; 2013; 5():77-84. PubMed ID: 23785244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
    Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
    Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
    Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
    Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
    Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation.
    Shilkrut M; Wu A; Thomas DG; Hamstra DA
    Mol Clin Oncol; 2014 May; 2(3):479-487. PubMed ID: 24772321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy.
    Qiao H; Huang X; Guo H; Liu Y; Yue C
    Pak J Med Sci; 2014; 30(6):1403-8. PubMed ID: 25674147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of Expression of ERCC1, RRM1 on Survival Trend of Lung Cancer with Cisplatin Combine Gemcitabine Chemotherapy after Surgical Resection.].
    Liang W; Hu C; Gu Q; Song M; Luo W
    Zhongguo Fei Ai Za Zhi; 2009 May; 12(5):403-7. PubMed ID: 20719134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.